Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Implications of ABCG2 Expression on Irinotecan Treatment of Colorectal Cancer Patients: A Review

7 Sept 2017

Abstract excerpt

Background: One of the main chemotherapeutic drugs used on a routine basis in patients with metastatic colorectal cancer ((m)CRC) is the topoisomerase-1 inhibitor, irinotecan. However, its usefulness is limited by the pre-existing or inevitable development of resistance. The ATP-binding cassette (ABC) transporter ABCG2/breast cancer resistance protein (BRCP) through its function in xenobiotic clearance might play...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Cells and Metastasis
Share to Cancer therapeutics and mechanisms
Share to Drug Transport and Resistance Mechanisms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 28880238
DOI: 10.3390/ijms18091926

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Implications of ABCG2 Expression on Irinotecan Treatment of Colorectal Cancer Patients: A ReviewPMID 28880238Read ↗

Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 yearsSemantic proximity Read ↗

ABCG2 overexpression in colon cancer cells resistant to SN38 and in irinotecan‐treated metastasesSemantic proximity Read ↗

Correlation between the promoter methylation status of ATP-binding cassette sub-family G member 2 and drug sensitivity in colorectal cancer cell linesSemantic proximity Read ↗

[Correlation of MDR1 and ABCG2 genetic polymorphisms with the efficacy and adverse events of irinotecan chemotherapy in patients with colorectal cancer].Semantic proximity Read ↗

ABCG2 Gene and ABCG2 Protein Expression in Colorectal Cancer—In Silico and Wet AnalysisSemantic proximity Read ↗

Pharmacogenetics of ABC and SLC transporters in metastatic colorectal cancer patients receiving first-line FOLFIRI treatment.Semantic proximity Read ↗

Gene and functional up-regulation of the BCRP/ABCG2 transporter in hepatocellular carcinomaSemantic proximity Read ↗

ABCG2 pharmacogenetics: ethnic differences in allele frequency and assessment of influence on irinotecan disposition.Semantic proximity Read ↗

Multidrug resistance protein 2 genetic polymorphism and colorectal cancer recurrence in patients receiving adjuvant FOLFOX-4 chemotherapy.Semantic proximity Read ↗

Topoisomerase I expression in tumors as a biological marker for CPT-11 chemosensitivity in patients with colorectal cancerSemantic proximity Read ↗

Increased Expression of Metallothionein Is Associated with Irinotecan Resistance in Gastric CancerSemantic proximity Read ↗

Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.